No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Indoco Remedies Limited, an Indian pharmaceutical company founded in Mumbai in 1945 (originally known as Indo Continental Trading Company), operates globally, manufacturing and distributing a broad spectrum of finished drug formulations and active pharmaceutical ingredients (APIs). The company's extensive product portfolio addresses diverse therapeutic areas: Respiratory conditions: with offerings like Karvol Plus, Febrex Plus, and Tuspel. Oral and dental care (stomatologicals): including Sensodent-K, Sensoform Toothpaste, the Rexidin series, and Snowdent. Gastrointestinal ailments: featuring products such as Carmicide, Cyclopam, and Nosic. Pain relief/analgesics: exemplified by Lignox and T-lac. Ophthalmic and otic solutions: comprising items like Renolen, Dexoren – S, and the Mofloren range. Vitamins, minerals, and nutritional supplements: such as Methycal, MCBM DHA, and Apispur. Urological treatments: including Carmicide and Cital. Dermatological preparations: like Cloben G and Scabex. Anti-infective agents: represented by ATM. Blood-related therapies: such as Hemsyl. Gynecological health products: including MCBM 69 and D Chiro. Anti-haemorrhoidal treatments: with Spear. Beyond its pharmaceutical manufacturing, Indoco Remedies provides comprehensive analytical services. These include impurity profiling, particle size analysis, heavy metal analysis, polymorphism studies, compatibility and stability assessments (like extractables/leachables and lyophilization), and advanced chromatographic method development and validation. Furthermore, the company offers a suite of engineering and project management services. This covers architectural and structural design, mechanical and electrical engineering, lighting solutions, control system integration, piping design, data transfer systems, and holistic project and construction management for process facilities. Indoco Remedies serves a wide range of medical professionals, from general practitioners and pediatricians to specialized consultants like dentists, cardiologists, diabetologists, endocrinologists, gynaecologists, and ophthalmologists.
www.indoco.comNo one on the platform currently holds INDOCO.NS.
No tracked institution reports a position in INDOCO.NS as of their last filing.
No one on the platform has traded INDOCO.NS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | 10.8% | 8.7% | ||||
| Profit Margin % | -5.3% | 2.9% | 3.5% | |||
| Free Cash Flow Margin % | -6.2% | -7.9% | -4.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $20.5B | +16.3% | $4.65 | $2.07–$7.49 | — | 2 |
| 2028 | $23.2B | +13.2% | $11.82 | $9.05–$13.33 | — | 4 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-28 | $-3.62 | $7.10 | +296.0% |
| 2026-05-07 | $-3.55 | $-2.30 | +35.2% |
| 2026-02-03 | $-2.55 | $-3.20 | -25.5% |
| 2025-10-22 | $-3.00 | $-0.80 | +73.3% |
| 2025-07-21 | $-3.00 | $-3.94 | -31.3% |
| 2025-05-22 | $-3.60 | $-4.48 | -24.4% |
| 2025-01-21 | $-1.50 | $-3.05 | -103.3% |
| 2024-10-24 | $1.75 | $-1.04 | -159.3% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| INDOCO.NSIndoco Remedies Limited | $241.39 | -8.22% | $22.2B | — |
| ALEMBICLTD.NSAlembic Limited | $100.51 | -3.66% | $25.8B | — |
| HIKAL.BOHikal Limited | $212.35 | -6.47% | $26.1B | — |
| HIKAL.NSHikal Limited | $212.22 | -5.66% | $26.2B | — |
| IOLCP.BOIOL Chemicals and Pharmaceuticals Limited |
| $179.45 |
| -7.26% |
| $52.7B |
| — |
| IOLCP.NSIOL Chemicals and Pharmaceuticals Limited | $179.52 | -7.61% | $52.7B | — |
| MOREPENLAB.BOMorepen Laboratories Limited | $106.25 | -8.37% | $58.3B | — |
Source: Financial Modeling Prep · peers by sector/industry